Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,470.00
Bid: 14,600.00
Ask: 10,510.00
Change: 106.00 (0.86%)
Spread: -4,090.00 (-28.014%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,364.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Strong End To Choppy Session On Tight US Poll

Wed, 04th Nov 2020 17:06

(Alliance News) - Stocks in London surged to a strong finish Wednesday as a tight US presidential election started to open up for Democratic challenger Joe Biden.

The FTSE 100 index got off to a sluggish start, but was able to close the session up 96.49 points, or 1.7% at 5,883.26 Wednesday. The blue-chip index had fallen by 1.0% to a low of 5,731.07 during a frenetic open.

The mid-cap FTSE 250 added 304.38 points, or 1.7%, at 17,796.08. The AIM All-Share closed up 15.36 points, 1.6%, at 974.74.

The Cboe UK 100 index closed up 1.7% at 584.13. The Cboe 250 ended up 1.5% at 14,961.24. The Cboe Small Companies grew 1.3% at 9,623.16.

The CAC 40 stock index in Paris advanced 2.4%, and Frankfurt's DAX 30 climbed 2.0%.

"It appears that once again investors are buying into a Joe Biden presidency, despite the race - which could still have days left in it yet - being on a knife-edge," SpreadEx analyst Connor Campbell said.

He continued: "Investors seem to be taking a kind of win-win attitude to the election. Yesterday's growth was based on the hopes of a blue wave led stimulus package. Now that the race is much tighter, and the Democrats have little chance of taking the Senate, the markets are celebrating the likelihood of preserved tax cuts and no healthcare reform."

President Donald Trump prematurely declared victory and sought Supreme Court intervention to stop vote-counting - even as his Democratic rival Joe Biden voiced confidence in his own chances.

Shattering norms in the world's most powerful democracy, Trump alleged "major fraud" as he held an upbeat rally inside the White House's ceremonial East Room.

Attention was again turning to three northern states that elected Trump four years ago - Michigan, Pennsylvania and Wisconsin - with early ballots still waiting to be counted from the Democratic stronghold cities of Detroit, Philadelphia and Milwaukee.

Pennsylvania Governor Tom Wolf said the state may not know its full election results on Wednesday. Wolf, a Democrat, urged patience, and said Pennsylvania intends to keep "the promise of democracy" that every vote counts.

Stocks in New York were in firmly green at the London equities close, with the Dow Jones Industrial Average up 2.4%, the S&P 500 index up 3.0%, and the Nasdaq Composite up 4.0%.

Oanda's Edward Moya said: "The Senate will likely stay red (that could change, but it is leaning heavily that way) and the Democrats House majority lead will shrink which means we won't see tax hikes, tougher regulation, and massive stimulus spending. The Nasdaq will outperform, and the great cyclical rotation won't happen anytime soon. Regardless of what happens with the presidential race over the next few days, financial markets are pricing a much more accommodative Fed and that should be bullish for US stocks."

In London, pharma firms were enjoying the potential split vote in the US, avoiding any regulations a Democratic-dominated Washington may have imposed.

AstraZeneca gained 6.6%, Hikma 2.5% and GlaxoSmithKline 4.4%.

IG senior market analyst Joshua Mahony added: "Astrazeneca has enjoyed a welcome boost in the wake of the news that the UK government could end up rolling out their vaccine as early as December. With Pfizer and Astrazeneca trials leading the way, much has been staked on the ability to find a suitable vaccine of from one of those two trials.

"For the short-term everyone has been caught up in election and lockdown fears, yet the ability to bring a vaccine to market out of these two front-runners will be critical in ensuring that we begin to see the end of this crisis."

Marks & Spencer added 5.1%. The retailer's interim performance was better than expected, despite swinging to a pretax loss of GBP87.6 million from a GBP158.8 million profit.

Revenue for the six months to September declined 16% to GBP4.09 billion from GBP4.86 billion a year before.

"Despite the company's historic loss, there are some encouraging signs in Marks & Spencer's update. The initial success of the Ocado partnership is highly promising and appears to be unlocking the food business's previously untapped online potential," said Brewin Dolphin Senior Investment Manager John Moore.

Ocado shares closed 5.3% higher.

Smurfit Kappa added 3.9%. The paper firm said its third-quarter performance was ahead of its expectations, with revenue year-to-date not far behind the prior year.

Dublin-based Smurfit reported revenue of EUR6.61 billion for the nine months ended September 30, down 3.5% from EUR6.85 billion the year before.

Smurfit also reported earnings before interest, tax, depreciation and amortisation of EUR1.13 billion, a 10% drop from EUR1.26 billion for the same period of 2019 but flat versus 2018's Ebitda figure.

Amid the chaos of the US election, blue-chip banks were bearing the brunt of the move into more defensive stocks, which is in stark contrast to the gains financials made on Tuesday prior to the polls closing in the US.

Standard Chartered lost 4.7% Wednesday, HSBC 4.2%, Barclays 2.6%, Lloyds 2.5% and NatWest 2.2%.

Defensive stocks, in contrast, fared bettered. Diageo added 3.6%, British American Tobacco 3.5% and BAE Systems 2.8%.

Turning to forex, the dollar had a strong start to the European session on Wednesday though its gains waned throughout the day.

The pound was quoted at USD1.2977 on Wednesday evening, down from USD1.3070 at the London equities close on Tuesday. However, sterling was as low as USD1.2915 earlier in trading.

The euro slipped to USD1.1710, from USD1.1729 late Tuesday.

Versus the yen, the dollar fetched JPY104.49, broadly flat from JPY104.50 at the London market close on Tuesday.

A barrel of the North Sea benchmark fetched USD40.62 Wednesday, up from USD39.64 a barrel at the London market close Tuesday.

Gold was quoted at USD1,901.50, down from USD1,906.10.

It's a big day in the international economic calendar Thursday, with interest rate decisions due from the Bank of England, at 0700 GMT, and the US Federal Reserve, at 1900 GMT.

Bank of America expects rising Covid-19 cases and restrictions, both in the UK and abroad, to cut the BoE's growth forecast for the UK economy by 40 basis points for 2020 and 140 basis points for 2021. The BoE now will likely model a GDP slide of 9.9% in 2020 and a rebound of 7.7% in 2021.

"In short we expect the BoE to continue moving from a 'V' to 'U'. Weaker growth should mean lower inflation at the policy relevant two-year horizon," Bank of America said, referring to the shape graph charting economic recovery.

Analysts are near unanimous in expecting the BoE to top up QE by a further GBP100 billion on Thursday in response to the darkening backdrop, after bumping up the programme by GBP100 billion in June to take the total stock of asset purchases to GBP745 billion.

Though it is all but certain the BoE will ease monetary policy this week, analysts don't think the bank will go as far as cutting interest rates into negative territory.

Elsewhere, there is a Jibun Bank services PMI print overnight, with Germany factory orders at 0600 GMT, and UK Markit construction PMI at 0930 GMT. Eurozone retail sales are due at 1000 GMT and the weekly US initial jobless claims are out at 1330 GMT.

In the UK corporate calendar, pharma giant AstraZeneca will issue third quarter results, blue chip grocer Sainsbury's, budget airline Wizz Air and Auto Trader will publish half-year results. Insurers RSA and Lancashire will release third quarter results.

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.